Sort   by:  
 Page size 
UnknownIncidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.
Not available
S-EPMC6312029 | biostudies-literature
UnknownDose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Not available
S-EPMC10912029 | biostudies-literature
UnknownCorrection: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Not available
S-EPMC11436350 | biostudies-literature
UnknownPonatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Not available
S-EPMC9804741 | biostudies-literature
UnknownPelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
Not available
S-EPMC12092244 | biostudies-literature
UnknownMEDULLOBLASTOMA
Not available
S-EPMC4046290 | biostudies-literature
Sort   by:  
 Page size